BeiGene Valuation

Is BGNE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BGNE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BGNE ($152.71) is trading below our estimate of fair value ($313.46)

Significantly Below Fair Value: BGNE is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for BGNE?

Other financial metrics that can be useful for relative valuation.

BGNE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.2x
Enterprise Value/EBITDA-14.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does BGNE's PS Ratio compare to its peers?

The above table shows the PS ratio for BGNE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9x
ALNY Alnylam Pharmaceuticals
9.3x19.6%US$18.7b
NTRA Natera
11.1x13.9%US$13.4b
NBIX Neurocrine Biosciences
7.1x13.6%US$14.0b
SRPT Sarepta Therapeutics
8.3x18.6%US$11.7b
BGNE BeiGene
5.8x19.1%US$16.0b

Price-To-Sales vs Peers: BGNE is good value based on its Price-To-Sales Ratio (5.8x) compared to the peer average (9.2x).


Price to Earnings Ratio vs Industry

How does BGNE's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a25.1%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a25.1%
n/an/an/a
No more companies

Price-To-Sales vs Industry: BGNE is good value based on its Price-To-Sales Ratio (5.8x) compared to the US Biotechs industry average (12.1x).


Price to Sales Ratio vs Fair Ratio

What is BGNE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BGNE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.8x
Fair PS Ratio10.5x

Price-To-Sales vs Fair Ratio: BGNE is good value based on its Price-To-Sales Ratio (5.8x) compared to the estimated Fair Price-To-Sales Ratio (10.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BGNE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$152.71
US$267.01
+74.9%
18.2%US$345.00US$152.00n/a21
May ’25US$156.53
US$268.40
+71.5%
19.2%US$345.00US$152.00n/a21
Apr ’25US$159.23
US$269.36
+69.2%
18.3%US$345.00US$161.00n/a21
Mar ’25US$165.02
US$270.08
+63.7%
17.4%US$345.00US$171.40n/a21
Feb ’25US$149.93
US$282.99
+88.7%
15.1%US$359.00US$196.00n/a19
Jan ’25US$180.36
US$285.19
+58.1%
15.3%US$359.00US$196.00n/a19
Dec ’24US$187.49
US$285.19
+52.1%
15.3%US$359.00US$196.00n/a19
Nov ’24US$181.30
US$287.65
+58.7%
16.4%US$359.00US$180.18n/a19
Oct ’24US$179.87
US$293.49
+63.2%
13.5%US$359.00US$196.00n/a20
Sep ’24US$208.92
US$295.74
+41.6%
13.1%US$359.00US$196.00n/a21
Aug ’24US$206.54
US$299.25
+44.9%
14.8%US$400.00US$196.00n/a21
Jul ’24US$178.30
US$308.39
+73.0%
12.9%US$400.00US$196.00n/a19
Jun ’24US$223.48
US$316.38
+41.6%
8.5%US$400.00US$263.30n/a20
May ’24US$259.98
US$310.77
+19.5%
9.6%US$400.00US$262.00US$156.5320
Apr ’24US$215.53
US$307.73
+42.8%
10.7%US$400.00US$230.10US$159.2321
Mar ’24US$235.88
US$310.06
+31.4%
10.9%US$400.00US$230.10US$165.0220
Feb ’24US$254.28
US$300.79
+18.3%
14.9%US$400.00US$213.00US$149.9319
Jan ’24US$219.94
US$264.98
+20.5%
18.1%US$400.00US$203.13US$180.3618
Dec ’23US$194.57
US$263.21
+35.3%
18.6%US$400.00US$203.13US$187.4918
Nov ’23US$169.43
US$264.55
+56.1%
18.8%US$400.00US$200.00US$181.3018
Oct ’23US$134.82
US$270.81
+100.9%
18.4%US$400.00US$177.00US$179.8716
Sep ’23US$171.10
US$273.83
+60.0%
18.6%US$400.00US$177.00US$208.9216
Aug ’23US$162.49
US$302.18
+86.0%
25.8%US$470.00US$177.00US$206.5415
Jul ’23US$166.95
US$308.64
+84.9%
24.7%US$470.00US$177.00US$178.3015
Jun ’23US$139.02
US$307.95
+121.5%
25.6%US$470.00US$177.00US$223.4814
May ’23US$160.00
US$332.12
+107.6%
19.8%US$470.00US$177.00US$259.9814

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.